The European cell sheet-based gene treatment market is experiencing significant growth. This industry is driven by an increasing need for innovative therapeutic solutions to address a broad range of genetic disorders. Successful clinical trials and regulatory sanctions are fueling market momentum. A key factor contributing to this situation is the